🇺🇸

US SEC Filing Intelligence

· daily

US SEC Trading Suspension Halt Orders — April 02, 2026

Across five US-listed small-cap companies, a cluster of Nasdaq and NYSE listing compliance failures emerged in late March-early April 2026, primarily driven by sub-$1.00 bid prices (3/5 filings), low market value of listed securities (1/5), governance issues (1/5), and insufficient market cap (1/5), signaling broad small-cap distress amid low valuations. No period-over-period financial trends like revenue growth or margins are detailed, but prior non-compliance periods (e.g., CytoSorbents' initial 180 days ending March 31, 2026) highlight persistent deterioration in stock price and market value metrics over 30-180 day windows. Most receive 180-day compliance extensions to September 2026 with no immediate delisting, except Solo Brands facing NYSE delisting proceedings starting April 2, 2026, and OTC transition. Sentiments skew negative/mixed (3 negative, 2 mixed), with high materiality (avg 9/10), implying elevated delisting risks, potential reverse splits, and liquidity erosion. Portfolio-level pattern: 4/5 emerging growth companies, concentrated Nasdaq issues (80%), pointing to sector-wide undervaluation or operational challenges in biotech/tech/consumer spaces. Market implications include heightened volatility, OTC trading discounts, and short-term trading opportunities around appeals/compliance catalysts.

5 high priority 5 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — April 02, 2026

Across 50 8-K filings in the USA Corporate Distress & Bankruptcy stream (39 new), distress signals dominate with 6 Nasdaq compliance failures (bid price/MVLS/audit committee deficiencies, extensions to Sep 2026), 4 reverse stock splits (1:20 to 1:25 ratios), 5+ debt forbearances/amendments/CRO appointments signaling liquidity crunches, and litigation settlements amid ongoing obligations. Counterbalancing positives include 10+ equity offerings/PP/IPOs raising $200M+ (e.g., $400M Caris loan, $42M Summit), debt exchanges/refinancings (e.g., Terra $25.6M secured notes), and M&A (Nuveen/PCAP acquisition Q2 2026). No explicit YoY/QoQ revenue/margin trends disclosed, but implied deteriorations from overadvances ($16M Borealis obligations), Nasdaq sub-$1 bids, and min cash covenants ($50M Caris). Portfolio-level: Small-cap biotechs/healthcare lead distress (12/50), with capital allocation skewed to dilutive raises vs dividends/buybacks (0 reported); insider activity limited to exec separations (#17 Cardiff $1.1M severance). Implications: Heightened bankruptcy risk in biotechs/SPACs, alpha in post-raise runways (e.g., OS Therapies to 2027), monitor Q2 catalysts like approvals/forbearance ends.

50 high priority 50 total filings
· daily

US Corporate Board Director Changes SEC Filings — April 02, 2026

Across 50 SEC 8-K filings on USA boardroom changes (42 new since last brief), C-suite turnover is elevated with 18 CFO/finance role shifts, 12 CEO/President changes, and 20 director/board adjustments, driven by retirements (10 cases), promotions (8), and experienced external hires (12). Sentiment skews positive/neutral (48/50), with 10 firms reaffirming 2026 guidance post-change (e.g., ESAB, Sally Beauty, Xerox), indicating continuity amid leadership refreshes; one negative (Regenerex CFO suspension) and one mixed (Kiora CDO departure). No broad revenue/margin declines; isolated YoY comp growth (Consumer Portfolio CEO +31%, Pres +44%) and bonus payouts (MAIA $362k total) signal strong FY2025 performance. Biotech (9 filings) and financials (8) lead activity, with net board size reductions in 5 cases. Implications: Positive for growth-oriented firms via M&A-savvy adds (Mama's Creations, Riverview); monitor interims (Oportun) for execution risk. Portfolio trend: Finance roles show +20% hire experience premium vs. average, no insider sales patterns.

50 high priority 50 total filings
· daily

US Merger & Acquisition SEC Filings — April 02, 2026

A surge in US M&A and takeover activity is evident across 20 filings on April 2, 2026, with 12 completions or announcements including strategic acquisitions in energy, pharma, retail, investment management, avionics, and buses, alongside 2 divestitures of non-core assets netting $24.8M and $70M cash respectively. SPACs dominate with 7 filings focused on unit separations, extensions, merger approvals, and amendments, signaling sustained deal hunting amid low redemptions (e.g., 1,153 shares in Tech & Tele). Positive sentiment prevails in 10/20 filings (50%), driven by accretive deals adding capacity (395MW Kodiak), AUM ($1.63B Bimini), revenue streams (Abundia Q2), and portfolio diversification, while mixed/neutral tones in divestitures and administrative updates. Period-over-period data limited but notable: Ashford pro forma revenue -1.6% YoY to $1.087B but net loss improved 16.5% to $157M excluding underperformer. No insider trading reported; forward-looking highlights include immediate accretion (Kodiak), Q2 revenue (Abundia), 2027 earnouts (Crown), and integration catalysts. Portfolio-level: M&A valuations range $200M-$1B EV, emphasizing bolt-ons for growth; implications point to sector consolidation in energy/industrials, SPAC revival.

20 high priority 20 total filings
· monthly

US Pre-Market SEC Filings Roundup — April 02, 2026

Overnight SEC filings reveal a heavy volume of proxy statements (20+ filings) signaling the ramp-up to May 2026 annual meetings, focusing on director elections, auditor ratifications, and equity plan approvals amid stable governance themes. Financial results are mixed: standout revenue growth in pharma (Pharming +26.6% YoY to $376M) and mining (Dynaresource +25.7% to $58M), contrasted by sharp declines in e-commerce (LightInTheBox -59.5% to $255M in 2024) and aesthetics (AirSculpt -15.8% FY25). M&A and restructuring activity is robust, including Kodiak's accretive $587M acquisition adding 395MW capacity and Suncrete's preferred stock exchange ahead of SPAC merger. Capital allocation leans shareholder-friendly with buybacks (FactSet $303M 6-mo, Lindsay $55M YTD, News Corp $1B program) and debt management (Transocean retiring $750M in 2026). Energy sector shines with Transocean's $1B backlog addition, while small-caps flag going concern risks (Mannatech, Algorhythm). Portfolio trend: 7/15 financial reporters show revenue growth averaging +15% YoY but mixed profitability; watch May catalysts for governance-driven volatility.

29 high priority 21 medium 50 total filings
· daily

Federal Construction & Infrastructure Contracts — April 01, 2026

Hensel Phelps Construction Co secured a $117M firm-fixed-price contract from USGS (DOI) for Hawaii facilities construction, with $84.3M (72%) already outlayed, providing strong revenue backlog through 2026. This sole award in the period highlights concentrated federal commitment to environmental infrastructure amid full-and-open competition. Execution risks from cost overruns and Hawaii logistics warrant monitoring, while $4.4M options offer upside.

1 total filings
· daily

DOD Defense Contracts Intelligence — April 01, 2026

Sevenson Environmental Services, Inc. secured a $180M (up to $199M with options) 8-year DoD contract for environmental remediation, signaling strong long-term revenue visibility for this small business. No funds outlaid yet delays near-term impact, but positions Sevenson for sustained growth in DoD cleanup efforts. Investors should monitor funding releases and options exercise amid execution risks over the 2024-2032 period.

1 total filings
· daily

Defense Manufacturing Contracts — April 01, 2026

Lockheed Martin benefits from a $301M NASA contract for MAVEN Mars project risk reduction, providing revenue visibility through Sep 2026 amid only 14% ($44M) outlayed to date. Remaining $257M obligation signals multi-year backlog in space manufacturing. Execution risks tied to performance-based award fees warrant monitoring, but long-term stability favors bullish positioning for institutional portfolios exposed to defense/space primes.

1 total filings
· daily

HHS & Healthcare Contracts Intelligence — April 01, 2026

Emergent BioSolutions secures $256M HHS contract for botulism antitoxin via Canadian subsidiary, providing multi-year revenue visibility to potential 2029 with $188M already outlayed. Bullish signal for steady biodefense revenue amid non-competed award, but firm-fixed-price structure and foreign ownership introduce execution and regulatory risks. Single large contract highlights HHS/ASPR focus on preparedness stockpiles, warranting monitoring for extensions.

1 total filings
· daily

New Federal Contractors — April 01, 2026

NASA commands 67% ($2.06B) of the $3.06B in new federal contract obligations, signaling sustained U.S. space investment through 2029+ with bullish awards to RTX/Raytheon ($1.22B), Lockheed ($301M), and others. Defense and environmental services see multi-year commitments to HII ($446M) and Sevenson ($180M), providing revenue backlogs amid 7/8 bullish signals. Long-duration cost-plus structures dominate, offering visibility but tying payouts to performance and appropriations.

8 total filings
· daily

Significant Contract Modifications ($10M+) — April 01, 2026

NASA dominates with $2.06B in long-term space contracts (67% of total value) to RTX/Raytheon, Lockheed Martin, TRAX, and Caltech/JPL, signaling sustained U.S. space investment through 2029 and bullish revenue visibility for aerospace primes. Additional $1B+ across DoD, HHS, GSA supports defense, health security, and environmental sectors via multi-year awards to HII, Emergent BioSolutions, and Sevenson. Overall bullish (7/8 signals) with $3.06B total obligations, but monitor funding outlays (avg. 40% disbursed) and appropriations risks amid extended timelines.

8 total filings
· daily

Contract Deobligations Alert — April 01, 2026

Eight contract deobligations alert $3.06B in total obligations, with 87% ($2.66B) tied to NASA and space-related work, signaling sustained U.S. government commitment to long-term aerospace projects through 2029 despite fiscal scrutiny. Bullish signals dominate (7/8) for primes like RTX, Lockheed Martin, and HII, driven by low-competition, cost-plus structures providing multi-year revenue visibility exceeding $900M in unobligated options. Risks center on execution over extended periods (avg. 10+ years) and funding dependencies, but opportunities in follow-ons favor sector leaders amid DoD/HHS diversification.

8 total filings
· daily

Contract Option Exercises — April 01, 2026

NASA dominates with $2.06B in long-term space contracts to RTX (Raytheon), Lockheed Martin, TRAX, and Caltech/JPL, signaling sustained U.S. space investment through 2029. Seven bullish signals across $3.06B total obligations highlight revenue visibility for defense primes and service providers via cost-plus structures. Key risks include execution over 5-18 year periods and funding dependencies on appropriations.

8 total filings
· daily

Federal Professional Services Contracts — April 01, 2026

HII Mission Technologies, subsidiary of Huntington Ingalls Industries, received a $446M obligated GSA engineering services award (potential $955M with options), underscoring robust federal demand in professional services. Unobligated options offer $509M near-term upside, but performance-tied fees and 2025 expiration introduce execution risks. This sole large contract highlights concentration risk in defense-adjacent engineering but signals potential for follow-ons.

1 total filings
· daily

NASA & Space Contracts Intelligence — April 01, 2026

NASA's two major ongoing contracts total $435M in obligations, with Lockheed Martin capturing a bullish $301M MAVEN Mars award (14% outlayed, $257M remaining through 2026) providing prime contractor revenue visibility. JPL's neutral $134M DSOC deep space comms project (73% outlayed, $36M remaining + $0.5M options to 2027) signals stable R&D funding. Cross-pattern: extended timelines highlight sustained deep space investment but expose execution and appropriation risks, favoring space primes with backlogs.

2 total filings
· daily

All HHS Contracts — April 01, 2026

Emergent BioSolutions Inc. benefits from a $256M HHS contract for botulism antitoxin, with $188M outlayed and potential extension to 2029, signaling multi-year revenue stability in biodefense. Non-competed award to its Canadian subsidiary underscores U.S. government reliance on the firm for critical countermeasures. Investors should monitor cost overrun risks in the firm fixed price structure and foreign ownership scrutiny amid geopolitical tensions.

1 total filings
· daily

Mega Contracts Monitor ($100M+) — April 01, 2026

NASA drives 67% ($2.06B) of $3.06B mega contracts, awarding long-term space engineering/logistics to RTX/Raytheon ($1.22B), Lockheed ($301M), TRAX ($406M), and Caltech ($134M) through 2026-2029, signaling robust U.S. space priorities. Defense/environmental (HII $446M, Sevenson $180M) and biodefense (Emergent $256M) add diversified bullish exposure with 8-18 year visibilities. Low outlays (avg. 40% funded) flag appropriation risks, but $100M+ options and follow-on potential favor primes.

8 total filings
· daily

High-Value Federal Grants ($5M+) — April 01, 2026

NASA dominates with $2.06B (67%) of $3.06B in high-value contracts, signaling sustained federal investment in space instrumentation, vehicles, and logistics through 2029, primarily bullish for RTX, Lockheed Martin, and support firms. Long-term cost-plus structures provide revenue visibility but tie payouts to performance amid funding risks. Defense, biotech, environmental remediation, and construction also secure multi-year commitments, with 7/8 bullish signals indicating broad stability in federal spending.

8 total filings
· daily

General Federal Contracts — April 01, 2026

NASA dominates with $2.06B across 4 contracts (67% of total), signaling robust long-term funding for space instruments, vehicles, and logistics through 2029, bullish for RTX, Lockheed Martin, and support firms. Broader $3.06B in bullish awards to defense, biotech, remediation, and construction firms highlight sustained federal spending on strategic priorities despite execution risks from extended timelines (avg. 8+ years). Institutional investors should prioritize aerospace/defense exposure while monitoring funding outlays averaging 35% complete.

8 total filings